{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:11:26Z","timestamp":1784193086786,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"DOI":"10.1093\/jac\/dkm150","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:40:56Z","timestamp":1181004056000},"page":"300-311","source":"Crossref","is-referenced-by-count":114,"title":["In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes"],"prefix":"10.1093","volume":"60","author":[{"given":"Shazad","family":"Mushtaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon\u00e9","family":"Kaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Livermore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,6,4]]},"reference":[{"key":"key\n\t\t\t\t20171013010446_DKM150C1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkf249","article-title":"In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci","volume":"50","author":"Jones","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/AAC.47.3.923-931.2003","article-title":"In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci","volume":"47","author":"Fujimura","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C3","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1128\/AAC.45.5.1422-1430.2001","article-title":"In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria","volume":"45","author":"Chamberland","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/AAC.46.2.321-326.2002","article-title":"In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci","volume":"46","author":"Johnson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000239452","article-title":"In vitro antibacterial activity of TOC-50, a new parenteral cephalosporin against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis","volume":"42","author":"Nomura","year":"1996","journal-title":"Chemotherapy"},{"key":"key\n\t\t\t\t20171013010446_DKM150C6","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-004-0309-3","article-title":"In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599","volume":"10","author":"Iizawa","year":"2004","journal-title":"J Infect Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"key\n\t\t\t\t20171013010446_DKM150C9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/48.suppl_1.87","article-title":"Interpretative reading: recognizing the universal and inferring resistance mechanisms from resistance phenotypes","volume":"48","author":"Livermore","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C10","first-page":"502","article-title":"\u03b2-Lactams: mode of action and mechanisms of bacterial resistance","volume-title":"Antibiotics in Laboratory Medicine","author":"Livermore","year":"1996"},{"key":"key\n\t\t\t\t20171013010446_DKM150C11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jac\/41.5.527","article-title":"Epidemiological typing of klebsiellae with extended-spectrum \u03b2-lactamases from European intensive care units","volume":"41","author":"Yuan","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C12","first-page":"203","article-title":"Molecular characterisation by PCR-restriction fragment length polymorphism of TEM \u03b2-lactamases","volume":"134","author":"Arlet","year":"1995","journal-title":"FEMS Microbiol Lett"},{"key":"key\n\t\t\t\t20171013010446_DKM150C13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized \u03b2-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/48.1.143","article-title":"Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS)","volume":"48","author":"Johnson","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1099\/00222615-25-3-227","article-title":"Chromosomal \u03b2-lactamase expression and antibiotic resistance in Enterobacter cloacae","volume":"25","author":"Yang","year":"1988","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20171013010446_DKM150C17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1469-0691.2006.01424.x","article-title":"Development of extended-spectrum activity in TEM \u03b2-lactamases in hyper-mutable, mutS Escherichia coli","volume":"12","author":"Ellington","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171013010446_DKM150C18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.8.4.557","article-title":"\u03b2-Lactamases in laboratory and clinical resistance","volume":"8","author":"Livermore","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171013010446_DKM150C19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/25.2.199","article-title":"Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I \u03b2-lactamases","volume":"25","author":"Akova","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1469-0691.2006.01403.x","article-title":"Can \u03b2-lactams be re-engineered to beat MRSA?","volume":"12","author":"Livermore","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171013010446_DKM150C21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/48.suppl_1.65","article-title":"Detection of methicillin\/oxacillin resistance in staphylococci","volume":"48","author":"Brown","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1469-0691.8.s.2.5.x","article-title":"Surveillance of resistance in bacteria causing community-acquired respiratory tract infections","volume":"8","author":"Felmingham","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171013010446_DKM150C23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0924-8579(02)00010-9","article-title":"Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN\u00ae) Database-USA","volume":"19","author":"Karlowsky","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171013010446_DKM150C24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1126\/science.8153626","article-title":"Resistance to antibiotics mediated by target alterations","volume":"264","author":"Spratt","year":"1994","journal-title":"Science"},{"key":"key\n\t\t\t\t20171013010446_DKM150C25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dki239","article-title":"CTX-M: changing the face of ESBLs in the UK","volume":"56","author":"Livermore","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013010446_DKM150C26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF02013107","article-title":"Clinical significance of \u03b2-lactamase induction and stable derepression in gram-negative rods","volume":"6","author":"Livermore","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"key\n\t\t\t\t20171013010446_DKM150C27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.diagmicrobio.2004.07.006","article-title":"The inoculum effect: fact or artifact?","volume":"50","author":"Craig","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171013010446_DKM150C28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/24.suppl_B.23","article-title":"Clavulanate and \u03b2-lactamase induction","volume":"24","author":"Livermore","year":"1989","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/60\/2\/300\/2097360\/dkm150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,28]],"date-time":"2019-04-28T17:57:47Z","timestamp":1556474267000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/60\/2\/300\/711883\/In-vitro-activity-of-ceftaroline-PPI0903M-T91825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,4]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,6,4]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkm150","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,8]]},"published":{"date-parts":[[2007,6,4]]}}}